VistaGen Therapeutics, a
biotech company using proprietary pluripotent stem cell technology for drug
rescue and regenerative medicine, has received from the Canadian Intellectual
Property Office a Notice of Allowance for Canadian patent No. 2,684,022,
entitled “Mesoderm and Definitive Endoderm Cell Populations.”
This patent, which is
exclusively licensed to VistaGen by the Icahn School of Medicine at Mount Sinai
in New York, will expand VistaGen’s intellectual property portfolio for
pluripotent stem cell culture systems that produce human cells of the endoderm
lineage, including liver, lung, pancreas, parathyroid and thyroid cells. The
patent enables the company to extend its research into the Canadian market and
follows the company’s recently awarded U.S. patent.
“This important Canadian
patent allowance extends our core intellectual property protection in a market
that has been strategically significant to us for many years,” Shawn K. Singh,
JD, VistaGen’s chief executive officer, stated in the news release. “In a
manner similar to our recently announced Notice of Allowance for its
counterpart, U.S. Patent Application 12/836,275, this new Canadian patent
allowance and our world-class differentiation and assay formulation expertise
put us in a strong position to pursue additional stem cell research projects in
Canada, especially innovative projects involving liver biology, customized drug
metabolism assays, and pilot nonclinical studies using pancreatic beta-islet
cells for drug and regenerative cell therapies for diabetes.”
For more information visit
http://www.vistagen.com/
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
